Amlodipine and angiotensin-converting enzyme inhibitor combination versus amlodipine monotherapy in hypertension: A meta-analysis of randomized controlled trials

Blood Pressure Monitoring

Volumn 15, Issue 4, 2010, Pages 195-204

  Lv, Yan ^a   Zou, Zui ^c   Chen, Guan Min ^d   Jia, Huai Xin ^b   Zhong, Jing ^a   Fang, Wei Wu ^a  

^a 302 MILITARY HOSPITAL   (China)

^b Department of Anesthesiology   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF CALGARY   (Canada)

Author keywords

amlodipine; angiotensin converting enzyme inhibitors; antihypertensive agents

Indexed keywords

ALACEPRIL; ALTIOPRIL; ALTIOPRIL CALCIUM; AMLODIPINE; AMLODIPINE BESYLATE; BENAZEPRIL; BENAZEPRILAT; CAPTOPRIL; CERANAPRIL; CILAZAPRIL; CILAZAPRILAT; DELAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENALAPRILAT; FOSINOPRIL; FOSINOPRILAT; IMIDAPRIL; LIBENZAPRIL; LISINOPRIL; MOEXIPRIL; OMAPATRILAT; PERINDOPRIL; PERINDOPRILAT; QUINAPRIL; QUINAPRILAT; RAMIPRIL; RAMIPRILAT; RENTIAPRIL; SARALASIN; UNINDEXED DRUG; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT;

ADVERSE OUTCOME; ARTHRALGIA; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COCHRANE LIBRARY; COMPARATIVE STUDY; COUGHING; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FLUSHING; HEADACHE; HEART PALPITATION; HUMAN; HYPERTENSION; META ANALYSIS; MONOTHERAPY; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PHARYNGITIS; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; DRUG COMBINATION; FEMALE; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY AND SPECIFICITY;

AMLODIPINE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 77954959656     PISSN: 13595237     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBP.0b013e32833a23d4     Document Type: Article

References (61)

1. Kannel WB. Fifty years of Framingham Study contributions to understanding hypertension. J Hum Hypertens 2000; 14:83-90.
2. Cutler JA. High blood pressure and end-organ damage. J Hypertens Suppl 1996; 14:S3-S6.
3. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365:217-223.
4. Gu D, Reynolds K, Wu X, Chen J, Duan X, Muntner P, et al. Prevalence, awareness, treatment, and control of hypertension in china. Hypertension 2002; 40:920-927.
5. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003; 289:2560-2572.
6. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, etal. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28:1462-1536.
7. Crawford MH. Combination therapy as first-line treatment for hypertension. Am J Cardiovasc Drugs 2009; 9:1-6.
8. Liu PH, Wang JD. Antihypertensive medication prescription patterns and time trends for newly-diagnosed uncomplicated hypertension patients in Taiwan. BMC Health Serv Res 2008; 8:133.
9. Mori H, Ukai H, Yamamoto H, Saitou S, Hirao K, Yamauchi M, Umemura S. Current status of antihypertensive prescription and associated blood pressure control in Japan. Hypertens Res 2006; 29:143-151.
10. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, etal.; The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350:757-764.
11. Liu L, Wang JG, Gong L, Liu G, Staessen JA, Systolic Hypertension in China (Syst-China) Collaborative Group. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. J Hypertens 1998;16 (12 Pt 1):1823-1829
12. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356:366-372.
13. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002; 288:2981-2997.
14. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366:895-906.
15. Gong L, Zhang W, Zhu Y, Zhu J, Kong D, Page V, et al. Shanghai trial of nifedipine in the elderly (STONE). J Hypertens 1996; 14:1237-1245.
16. Lindholm LH. Valsartan treatment of hypertension-does VALUE add value? Lancet 2004; 363:2010-2011.
17. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, etal.; HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351:1755-1762. (Pubitemid 28269185)
18. Gu Q, Paulose-Ram R, Dillon C, Burt V. Antihypertensive medication use among US adults with hypertension. Circulation 2006; 113: 213-221.
19. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288:2421-2431.
20. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355:253-259.
21. Higgins J, Altman D. Chapter 8: assessing risk of bias in included studies. Cochrane handbook for systematic reviews of interventions version. 5.0.2. 2009
22. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177-188.
23. Follmann D, Elliott P, Suh I, Cutler J. Variance imputation for overviews of clinical trials with continuous response. J Clin Epidemiol 1992; 45:769-773.
24. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50:1088-1101.
25. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000; 56:455-463.
26. Sutton AJ, Duval SJ,Tweedie RL, Abrams KR, Jones DR. Empirical assessment of effect of publication bias on meta-analyses. BMJ 2000; 320:1574-1577.
27. Fogari R, Malamani GD, Zoppi A, Mugellini A, Rinaldi A, Vanasia A, Preti P. Effect of benazepril addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens 2003; 17:207-212.
28. Fogari R, Preti P, Lazzari P, Corradi L, Zoppi A, Fogari E, Mugellini A. Effect of benazepril amlodipine combination on fibrinolysis in hypertensive diabetic patients. Eur J Clin Pharmacol 2003; 59:271-275.
29. Jamerson KA, Nwose O, Jean-Louis L, Schofield L, Purkayastha D, Baron M. Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension. Am J Hypertens 2004; 17:495-501.
30. Kuschnir E, Acuna E, Sevilla D, Vasquez J, Bendersky M, Resk J, Glazer R. Treatment of patients with essential hypertension: amlodipine 5 mg/benazepril 20 mg compared with amlodipine 5mg, benazepril 20mg, and placebo. Clin Ther 1996; 18:1213-1224.
31. Messerli FH, Oparil S, Feng Z. Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension. Am J Cardiol 2000; 86:1182-1 187.
32. Neutel JM, Smith DH, Weber MA. Effect of antihypertensive monotherapy and combination therapy on arterial distensibility and left ventricular mass. Am J Hypertens 2004; 17:37-42.
33. Neutel JM, Smith DH, Weber MA, Schofield L, Purkayastha D, Gatlin M. Efficacy of combination therapy with amlodipine besylate/benazepril hydrochloride for lowering systolic blood pressure in stage 2 hypertension. Am J Geriatr Cardiol 2006; 15:142-150.
34. Pool J, Kaihlanen P, Lewis G, Ginsberg D, Oparil S, Glazer R, Messerli FH. Once-daily treatment of patients with hypertension: a placebo-controlled study of amlodipine and benazepril vs amlodipine or benazepril alone. J Hum Hypertens 2001; 15:495-498.
35. Chrysant SG, Sugimoto DH, Lefkowitz M, Salko T, Khan M, Arora V, Shi V. The effects of high-dose amlodipine/benazepril combination therapies on blood pressure reduction in patients not adequately controlled with amlodipine monotherapy. Blood Press 2007; 1:10-17
36. Mohler ER III, Herrington D, Ouyang P, Mangano C, Ritter S, Davis P, et al. A randomized, double-blind trial comparing the effects of amlodipine besylate/benazepril HCl vs amlodipine on endothelial function and blood pressure. J Clin Hypertens 2006; 8:692-698.
37. Ueng KC, Lin LC, Voon WC, Lin MC, Liu YB, Su HM, et al. An eight-week, multicenter, randomized, double-blind study to evaluate the efficacy and tolerability of fixed-dose amlodipine/benazepril combination in comparison with amlodipine as first-line therapy in chinese patients with mild to moderate hypertension. Blood Press 2008; 1:24-31.
38. Cappuccio FP, Markandu ND, Singer DR, MacGregor GA. Amlodipine and lisinopril in combination for the treatment of essential hypertension: efficacy and predictors of response. J Hypertens 1993; 11:839-847
39. Naidu MU, Usha PR, Rao TR, Shobha JC. Evaluation of amlodipine, lisinopril, and a combination in the treatment of essential hypertension. Postgrad Med J 2000; 76:350-353.
40. Brown MJ, Dickerson JE. Alpha-blockade and calcium antagonism: an effective and well-tolerated combination for the treatment of resistant hypertension. J Hypertens 1995; 13:701-707
41. MacGregor MS, Deighan CJ, Rodger RS, Boulton-Jones JM. A prospective open-label randomised trial of quinapril and/or amlodipine in progressive non-diabetic renal failure. Nephron 2005; 101:c139-c149.
42. Miranda RD, Mion D Jr, Rocha JC, Kohlmann O Jr, Gomes MA, Saraiva JF, et al. An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study. Clin Ther 2008; 30:1618-1628
43. Fogari R, Preti P, Zoppi A, Rinaldi A, Corradi L, Pasotti C, et al. Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients. Am J Hypertens 2002; 15:1042-1049.
44. Phillips RA, Kloner RA, Grimm RH Jr, Weinberger M. The effects of amlodipine compared to losartan in patients with mild to moderately severe hypertension. J Clin Hypertens 2003; 5:17-23.
45. Marin-Iranzo R, de la Sierra-Iserte A, Roca-Cusachs A, Olivan-Martinez J, Redon-Mas J, Luque-Otero M, et al. Double blind study of the efficacy and safety of the fixed dose combination of enalapril 10 mg/nitrendipine 20 mg versus the increase of amlopidine dose in essential hypertensive patients not controlled with amlodipine 5 mg. Rev Clin Esp 2005; 205:418-424.
46. Kohlmann Junior O, Jardim PC, Oigman W. Brazilian multicenter study on efficacy and tolerability of trandolapril in mild-to-moderate essential arterial hypertension. EMBATHE substudy with ambulatory blood pressure monitoring. Arq Bras Cardiol 1999; 72:547-557.
47. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 1993; 328:914-921.
48. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42:1206-1252.
49. Skolnik NS, Beck JD, Clark M. Combination antihypertensive drugs: recommendations for use. Am Fam Physician 2000; 61:3049-3056.
50. Frishman WH, Ram CV, McMahon FG, Chrysant SG, Graff A, Kupiec JW, Hsu H, The Benazepril/Amlodipine Study Group. Comparison of amlodipine and benazepril monotherapy to amlodipine plus benazepril in patients with systemic hypertension: a randomized, double-blind, placebo-controlled, parallel-group study. J Clin Pharmacol 1995; 35:1060-1066.
51. Gradman AH, Cutler NR, Davis PJ, Robbins JA, Weiss RJ, Wood BC, Enalapril-Felodipine ER Factorial Study Group. Combined enalapril and felodipine extended release (ER) for systemic hypertension. Am J Cardiol 1997; 79:431-435.
52. Chrysant SG, Gavras H, Niederman AL, Marbury TC, Goldstein R, Long-term Use of Enalapril/Diltiazem ER in Stage 3-4 Hypertension Group. Clinical utility of long-term enalapril/diltiazem ER in stage 3-4 essential hypertension. J Clin Pharmacol 1997; 37:810-815.
53. DeQuattro V, Lee D, Trandolapril Study Group. Fixed-dose combination therapy with trandolapril and verapamil SR is effective in primary hypertension. Am J Hypertens 1997; 10 (7 Pt 2):138S-145S.
54. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327:685-691.
55. Ambrosioni E, Borghi C, Magnani B, The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995; 332:80-85.
56. Rutherford JD, Pfeffer MA, Moye LA, Davis BR, Flaker GC, Kowey PR, etal.; SAVE Investigators. Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. Circulation 1994; 90:1731-1738.
57. Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, et al.; Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995; 333:1670-1676.
58. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G, The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342:145-153. (Pubitemid 30051645)
59. Dzau VJ. Theodore cooper lecture: tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001; 37: 1047-1052.
60. Cohen DL, Townsend RR. Will the results of the ACCOMPLISH trial affect the recommendations of JNC 8? J Clin Hypertens 2009; 11:100-101.
61. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348:583-592.